Testa Stefano, Riera Carles Sánchez, Fornetti Ersilia, Riccio Federica, Fuoco Claudia, Bernardini Sergio, Baldi Jacopo, Costantini Marco, Foddai Maria Laura, Cannata Stefano, Gargioli Cesare
Department of Biology, University of Rome Tor Vergata, Rome, Italy.
IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Front Physiol. 2020 Sep 16;11:553198. doi: 10.3389/fphys.2020.553198. eCollection 2020.
Skeletal muscle tissue is characterized by restrained self-regenerative capabilities, being ineffective in relation to trauma extension both in time span (e.g., chronic diseases) and in size (e.g., large trauma). For these reasons, tissue engineering and/or cellular therapies represent a valuable solution in the cases where the physiological healing process failed. Satellite cells, the putative skeletal muscle stem cells, have been the first solution explored to remedy the insufficient self-regeneration capacity. Nevertheless, some limitation related to donor age, muscle condition, expansion hitch, and myogenic potentiality maintenance have limited their use as therapeutic tool. To overcome this hindrance, different stem cells population with myogenic capabilities have been investigated to evaluate their real potentiality for therapeutic approaches, but, as of today, the perfect cell candidate has not been identified yet. In this work, we analyze the characteristics of skeletal muscle-derived human Mesenchymal Stem Cells (hMSCs), showing the maintenance/increment of myogenic activity upon differential culture conditions. In particular, we investigate the influence of a commercial enriched growth medium (Cyto-Grow), and of a medium enriched with either human-derived serum (H.S.) or human Platelet-rich Plasma (PrP), in order to set up a culture protocol useful for employing this cell population in clinical therapeutic strategies. The presented results reveal that both the enriched medium (Cyto-Grow) and the human-derived supplements (H.S. and PrP) have remarkable effects on hMSCs proliferation and myogenic differentiation compared to standard condition, uncovering the real possibility to exploit these human derivatives to ameliorate stem cells yield and efficacy.
骨骼肌组织的特点是自我再生能力有限,无论是在时间跨度(如慢性疾病)还是在大小(如大面积创伤)方面,对于创伤的扩展都无能为力。由于这些原因,在生理愈合过程失败的情况下,组织工程和/或细胞疗法是一种有价值的解决方案。卫星细胞,即公认的骨骼肌干细胞,是最早被探索用于弥补自我再生能力不足的解决方案。然而,一些与供体年龄、肌肉状况、扩增障碍和肌源性潜能维持相关的限制,限制了它们作为治疗工具的应用。为了克服这一障碍,人们研究了具有肌源性能力的不同干细胞群体,以评估它们在治疗方法中的实际潜力,但截至目前,尚未确定完美的细胞候选者。在这项工作中,我们分析了骨骼肌来源的人间充质干细胞(hMSCs)的特性,展示了在不同培养条件下肌源性活性的维持/增加。特别是,我们研究了一种商业富集生长培养基(Cyto-Grow)以及富含人源血清(H.S.)或富含人血小板血浆(PrP)的培养基的影响,以便建立一种有助于在临床治疗策略中应用这种细胞群体的培养方案。呈现的结果表明,与标准条件相比,富集培养基(Cyto-Grow)和人源补充剂(H.S.和PrP)对hMSCs的增殖和肌源性分化都有显著影响,揭示了利用这些人源衍生物改善干细胞产量和功效的实际可能性。